Abstract
The following results were obtained through the fundamental and clinical studies of aztreonam (AZT), a new monobactam antibiotic, in obstetrics and gynecology.
1. Satisfactory tissue penetration was not recognized in 3-5 hours after intravenous injection of 1g. However, the concentration was more than MIC for the majority of aerobic Gram-negative bacteria in intravenous drip infusion of AZT 1g and in intravenous injection and intravenous drip infusion of 2g.
2. There was no difference of serum concentration of AZT between uterine arterial blood and cubital venous blood.
3. AZT was administered by intravenous drip infusion to 2 cases of puerperal endometritis, 2 cases (the same patient) of vaginal wall abscess, 1 case of postoperative lymphocele infection and 1 case of infected ovarian cyst suspected, and it was effective for all of them.
4. Neither subjective/objective side effects nor abnormal laboratory findings were noted in any case.
